Jenkins, V, Fallowfield, L, Edginton, T, Payne, H and Hamilton, E (2005) Preferences of healthy men for two different endocrine treatment options offered for locally advanced prostate cancer. Current Medical Research and Opinion, 21 (9). pp. 1329-1335. ISSN 0300-7995Full text not available from this repository.
The aim of this study was to determine whether healthy men would prefer either luteinizing hormone releasing hormone analogues (LHRHa) or non-steroidal anti-androgen therapy (NSAA) should they hypothetically develop locally advanced prostate cancer.
PARTICIPANTS AND METHODS:
A representative sample of 180 men without prostate cancer (68% over 65 years of age, range 50-90 years), read two scenarios describing LHRHa or NSAA treatments for locally advanced prostate cancer. Participants chose which drug treatment they hypothetically would prefer, gave a reason for their choice and indicated the degree to which they wanted to avoid side effects specific to each drug.
Eighty-six per cent (156/180) of the men chose NSAA therapy, 7% (12/180) chose LHRHa therapy and 7% (12/180) could not decide. The main reason men chose LHRHa therapy was because of the method of administration (9/12) whereas those who chose NSAA therapy cited avoidance of the side effects associated with LHRHa treatment (115/156). The side effects, ranked in order of importance, that men who chose NSAA therapy most wanted to avoid included risk of potential fractures (85%), reduced physical strength (76%), decreased sexual interest (56%), impotence (51%), hot flushes (49%), breast enlargement (17%) and breast tenderness (13%).
Although this project was a hypothetical study, several important issues emerged from the data that are relevant to patient choice. Men should be fully informed about the side-effect profiles of different endocrine treatments, involved in decision making and allowed to choose therapies less likely to cause side effects they would prefer to avoid.
|Keywords:||LHRHa, Locally advanced prostate cancer, NSAA, Patient choice|
|Schools and Departments:||Brighton and Sussex Medical School > Sussex Health Outcomes Research & Education in Cancer (SHORE-C)|
|Subjects:||R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens
|Depositing User:||Jil Fairclough|
|Date Deposited:||18 Apr 2012 11:15|
|Last Modified:||30 Nov 2012 16:56|